Pluri Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Pluri Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.34M | Sep 17, 2025 |
| FY2025 | Jun 30, 2024 | $326.0K | Sep 17, 2025 |
| FY2024 | Jun 30, 2023 | $287.0K | Sep 18, 2024 |
| FY2023 | Jun 30, 2022 | $234.0K | Sep 12, 2023 |
| FY2021 | Jun 30, 2020 | $23.0K | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | $54.0K | Sep 10, 2020 |
| FY2020 | Jun 30, 2018 | $50.0K | Sep 10, 2020 |
| FY2018 | Jun 30, 2016 | $2.85M | Sep 12, 2018 |
| FY2017 | Jun 30, 2015 | $379.0K | Sep 7, 2017 |
| FY2016 | Jun 30, 2014 | $379.0K | Sep 7, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $654.0K | Sep 17, 2025 |
| FY2025 | Jun 30, 2024 | $322.0K | Sep 17, 2025 |
| FY2024 | Jun 30, 2023 | $278.0K | Sep 18, 2024 |
| FY2023 | Jun 30, 2022 | $234.0K | Sep 12, 2023 |
| FY2021 | Jun 30, 2020 | $23.0K | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | $52.0K | Sep 10, 2020 |
| FY2020 | Jun 30, 2018 | $48.0K | Sep 10, 2020 |
| FY2018 | Jun 30, 2016 | $2.75M | Sep 12, 2018 |
| FY2017 | Jun 30, 2015 | $366.0K | Sep 7, 2017 |
| FY2016 | Jun 30, 2014 | $368.0K | Sep 7, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($22.58M) | Sep 17, 2025 |
| FY2025 | Jun 30, 2024 | ($20.89M) | Sep 17, 2025 |
| FY2024 | Jun 30, 2023 | ($28.32M) | Sep 18, 2024 |
| FY2023 | Jun 30, 2022 | ($41.24M) | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | ($49.87M) | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | ($29.15M) | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | ($35.31M) | Sep 10, 2020 |
| FY2020 | Jun 30, 2018 | ($26.13M) | Sep 10, 2020 |
| FY2019 | Jun 30, 2017 | ($27.81M) | Sep 12, 2019 |
| FY2018 | Jun 30, 2016 | ($23.25M) | Sep 12, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($22.18M) | Sep 17, 2025 |
| FY2025 | Jun 30, 2024 | ($22.16M) | Sep 17, 2025 |
| FY2024 | Jun 30, 2023 | ($27.25M) | Sep 18, 2024 |
| FY2023 | Jun 30, 2022 | ($41.59M) | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | ($50.62M) | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | ($29.48M) | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | ($35.53M) | Sep 10, 2020 |
| FY2020 | Jun 30, 2018 | ($33.73M) | Sep 10, 2020 |
| FY2019 | Jun 30, 2017 | ($28.02M) | Sep 12, 2019 |
| FY2018 | Jun 30, 2016 | ($23.32M) | Sep 12, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $12.85M | Sep 17, 2025 |
| FY2025 | Jun 30, 2024 | $12.45M | Sep 17, 2025 |
| FY2024 | Jun 30, 2023 | $15.75M | Sep 18, 2024 |
| FY2023 | Jun 30, 2022 | $24.61M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $30.53M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | $23.10M | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | $29.88M | Sep 10, 2020 |
| FY2020 | Jun 30, 2018 | $26.37M | Sep 10, 2020 |
| FY2019 | Jun 30, 2017 | $24.00M | Sep 12, 2019 |
| FY2018 | Jun 30, 2016 | $22.86M | Sep 12, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($18.21M) | Sep 17, 2025 |
| FY2025 | Jun 30, 2024 | ($18.02M) | Sep 17, 2025 |
| FY2024 | Jun 30, 2023 | ($22.86M) | Sep 18, 2024 |
| FY2023 | Jun 30, 2022 | ($36.50M) | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | ($30.91M) | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | ($26.37M) | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | ($29.45M) | Sep 10, 2020 |
| FY2020 | Jun 30, 2018 | ($21.38M) | Sep 10, 2020 |
| FY2019 | Jun 30, 2017 | ($21.61M) | Sep 12, 2019 |
| FY2018 | Jun 30, 2016 | ($18.52M) | Sep 12, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.62M | Sep 17, 2025 |
| FY2025 | Jun 30, 2024 | $323.0K | Sep 17, 2025 |
| FY2024 | Jun 30, 2023 | $262.0K | Sep 18, 2024 |
| FY2023 | Jun 30, 2022 | $280.0K | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $373.0K | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | $270.0K | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | $239.0K | Sep 10, 2020 |
| FY2020 | Jun 30, 2018 | $342.0K | Sep 10, 2020 |
| FY2019 | Jun 30, 2017 | $378.0K | Sep 12, 2019 |
| FY2018 | Jun 30, 2016 | $1.75M | Sep 12, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $38.68M | Sep 17, 2025 |
| FY2025 | Jun 30, 2024 | $39.53M | Sep 17, 2025 |
| FY2024 | Jun 30, 2023 | $50.80M | Sep 18, 2024 |
| FY2023 | Jun 30, 2022 | $68.07M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $93.54M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | $65.53M | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | $31.31M | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | $38.96M | Sep 12, 2019 |
| FY2018 | Jun 30, 2017 | $37.53M | Sep 12, 2018 |
| FY2017 | Jun 30, 2016 | $45.94M | Sep 7, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($6.84M) | Sep 17, 2025 |
| FY2025 | Jun 30, 2024 | $96.0K | Sep 17, 2025 |
| FY2024 | Jun 30, 2023 | $13.36M | Sep 18, 2024 |
| FY2023 | Jun 30, 2022 | $30.04M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $57.15M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | $56.10M | Sep 13, 2021 |
| FY2021 | Jun 30, 2019 | $21.82M | Sep 13, 2021 |
| FY2020 | Jun 30, 2018 | $28.51M | Sep 10, 2020 |
| FY2020 | Jun 30, 2017 | $30.25M | Sep 10, 2020 |
| FY2019 | Jun 30, 2016 | $38.16M | Sep 12, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.14M | Sep 17, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($443.06M) | Sep 17, 2025 |
| FY2025 | Jun 30, 2024 | ($420.47M) | Sep 17, 2025 |
| FY2024 | Jun 30, 2023 | ($399.58M) | Sep 18, 2024 |
| FY2023 | Jun 30, 2022 | ($371.26M) | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | ($330.02M) | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | ($280.16M) | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | ($251.00M) | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | ($215.70M) | Sep 12, 2019 |
| FY2018 | Jun 30, 2017 | ($189.57M) | Sep 12, 2018 |
| FY2017 | Jun 30, 2016 | ($161.76M) | Sep 7, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $5.90M | Sep 17, 2025 |
| FY2025 | Jun 30, 2024 | $6.78M | Sep 17, 2025 |
| FY2024 | Jun 30, 2023 | $5.36M | Sep 18, 2024 |
| FY2023 | Jun 30, 2022 | $9.77M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | $31.24M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | $8.27M | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | $4.11M | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | $8.82M | Sep 12, 2019 |
| FY2019 | Jun 30, 2017 | $4.71M | Sep 12, 2019 |
| FY2018 | Jun 30, 2016 | $6.22M | Sep 12, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (3) | Sep 17, 2025 |
| FY2025 | Jun 30, 2024 | (3) | Sep 17, 2025 |
| FY2024 | Jun 30, 2023 | (6) | Sep 18, 2024 |
| FY2023 | Jun 30, 2022 | (1) | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | (1) | Sep 21, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (3) | Sep 17, 2025 |
| FY2025 | Jun 30, 2024 | (3) | Sep 17, 2025 |
| FY2024 | Jun 30, 2023 | (6) | Sep 18, 2024 |
| FY2023 | Jun 30, 2022 | (1) | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | (1) | Sep 21, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 7.89M | Sep 17, 2025 |
| FY2025 | Jun 30, 2024 | 5.41M | Sep 17, 2025 |
| FY2024 | Jun 30, 2023 | 5.16M | Sep 18, 2024 |
| FY2023 | Jun 30, 2022 | 32.51M | Sep 12, 2023 |
| FY2022 | Jun 30, 2021 | 31.96M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | 25.49M | Sep 13, 2021 |
| FY2020 | Jun 30, 2019 | 15.08M | Sep 10, 2020 |
| FY2019 | Jun 30, 2018 | 11.36M | Sep 12, 2019 |
| FY2018 | Jun 30, 2017 | 96.94M | Sep 12, 2018 |
| FY2017 | Jun 30, 2016 | 80.27M | Sep 7, 2017 |